Brief: Biomerieux Q3 2024 +11% Organic Sales Growth At €969M
Oct 30 (Reuters) - Biomerieux SA BIOX.PA :
* +11% ORGANIC SALES GROWTH IN Q3 2024 AT €969M
* CONFIRMATION OF THE 2024 FULL YEAR REVISED GUIDANCE
* FY OUTLOOK: CURRENCY EFFECT NEGATIVE IMPACT AROUND €60MLN
ON
ANNUAL CEBIT VERSUS AROUND €70M PREVIOUSLY
Source text: [https://tinyurl.com/4a2jhrhs]
Further company coverage: BIOX.PA
(Reporting by Hugo Lhomedet)
((Hugo.Lhomedet@thomsonreuters.com;))
Recent news on Biomerieux SA
See all newsBrief: Biomerieux Receives US FDA 510(K) Clearance And Ivdr CE Marking For Vitek Pro
Brief: bioMerieux Receives FDA Clearance For Latest Versions Of Biofire® Filmarray
Europe Research Roundup: Asos, Erste Group, SCHOTT pharma
Europe Research Roundup: Acceler8 Ventures, Hermes, Soitec
BioMerieux shares rise after Q3 sales beat